The Latest Advancement in Regenerative Medicine Is Lab-Grown Vaginas

Medical research continues to succeed in engineering organs. But that’s not enough.

Yes, that is what the headline implies.
National Journal
Brian Resnick
Add to Briefcase
Brian Resnick
April 10, 2014, 2:30 p.m.

Add nos­trils and va­gi­nas to the read­ily ex­pand­ing list of hu­man tis­sues doc­tors can now grow in labor­at­or­ies and suc­cess­fully im­plant in pa­tients.

Two long-term stud­ies just pub­lished in the in­flu­en­tial med­ic­al journ­al The Lan­cet out­line the suc­cess doc­tors have achieved in trans­plant­ing both body parts. In the first study, doc­tors at Wake Forest Uni­versity har­ves­ted cells from the gen­it­als of four teen­age girls born with a syn­drome that res­ults in un­der­developed sexu­al or­gans, coaxed those cells in­to a re­gen­er­at­ive state, grew them on a scaf­fold, and then trans­planted the res­ult­ing tis­sue.

After eight years of fol­low up, “the or­gans con­tin­ue to func­tion as if they were nat­ive tis­sue and all re­cip­i­ents are sexu­ally act­ive, re­port no pain, and are sat­is­fied with their de­sire/arous­al, lub­ric­a­tion, and or­gasm.”

In the second study, five people had their nos­trils re­con­struc­ted with their own car­til­age. That tis­sue was har­ves­ted from their own noses, and coaxed in­to ex­pand­ing in volume by a factor of 40. It was then im­planted. The re­search con­cludes that “the clin­ic­al re­con­struc­tion of the nas­al [lobe] after re­sec­tion of a non-melan­oma skin can­cer is safe and feas­ible.”

While these find­ings are cer­tainly eye­brow-rais­ing — and lend hope to those suf­fer­ing with dis­fig­ur­a­tion — the more im­port­ant as­pect of their pub­lic­a­tion can be found in an op-ed pub­lished along­side the re­search.

Drs. Mar­tin A. Birch­all, and Al­ex­an­der M. Sei­fali­an write that these find­ings can be just as frus­trat­ing as they are prom­ising. This re­search is con­sidered dis­rupt­ive medi­cine, and dis­rup­tions can take a very, very long time to make their way in­to main­stream medi­cine. And the high cost of de­vel­op­ing such tech­no­logy of­ten poses road­b­locks. Birch­all and Sei­fali­an write:

MRI scan­ners con­tin­ue to im­prove gen­er­a­tion­ally. These changes, which im­prove the pa­tient’s ex­per­i­ence and ac­cur­acy of dia­gnos­is, are sus­tain­ing in­nov­a­tions: they im­prove an ex­ist­ing sys­tem that is un­der­stood by pa­tients and that sup­ports spe­cial­ised in­dustry, doc­tors, and health-care sys­tems. By con­trast, tis­sue en­gin­eer­ing, and the vari­ous shades of re­gen­er­at­ive and cel­lu­lar ther­apies it part­ners, is a dis­rupt­ive tech­no­logy. …

Early auto­mobile tech­no­logy, al­though highly in­nov­at­ive, was the pre­serve of those who could af­ford it for many years. It was only when Henry Ford’s mass pro­duc­tion brought auto­mo­biles to every­one’s street, in num­bers yet at af­ford­able cost, that the in­dustry of the horse-drawn car­riage passed away. These two Lan­cet stud­ies show that those who prac­tise con­ven­tion­al tis­sue re­con­struc­tion and or­gan trans­plant­a­tion, and the health-care and com­mer­cial in­dus­tries which sup­port them, should fi­nally be tak­ing the quirky min­nows of tis­sue en­gin­eer­ing quite ser­i­ously. Dis­rupt­ive in­nov­a­tion might be nigh.

As I wrote in Novem­ber, it will be some time be­fore lab-grown or­gans are com­monly avail­able. Clin­ic­al tri­als for new pro­ced­ures take dec­ades. And “private in­dustry is go­ing to have to raise mil­lions and mil­lions of dol­lars not around the sci­ence, but around the prac­tic­al­ity,” Wil­li­am Wag­n­er, dir­ect­or of re­gen­er­at­ive medi­cine at the Uni­versity of Pitt­s­burgh, told me then.

Road­b­locks in­volving time and money are not ex­clus­ive to re­gen­er­at­ive medi­cine. Take an­ti­bi­ot­ic re­search. Ap­provals of new an­ti­bi­ot­ics are cur­rently at their low­est rate, at a time when threat of drug-res­ist­ant strains haven’t been high­er. Or even sun­screen. In­gredi­ents that European com­pan­ies have been us­ing for years, which work bet­ter than the ones cur­rently avail­able in the United States, are stuck in reg­u­lat­ory limbo.

That’s why Birch­all and Sei­fali­an provide a good re­mind­er: Let’s turn some of these gee-whiz stud­ies in­to real­ity.

What We're Following See More »
ANOTHER GOP MODERATE TO HER SIDE
John Warner to Endorse Clinton
8 hours ago
THE LATEST

"Democratic presidential nominee Hillary Clinton will score another high-powered Republican endorsement on Wednesday, according to a campaign aide: retired senator John Warner of Virginia, a popular GOP maverick with renowned military credentials."

Source:
AUTHORITY OF EPA IN QUESTION
Appeals Court Hears Clean Power Plant Case
8 hours ago
THE LATEST

The U.S. Court of Appeals for the District of Columbia Circuit on Tuesday "heard several hours of oral arguments" over the Environmental Protection Agency's Clean Power Plan rules. The 10-judge panel "focused much of their questioning on whether the EPA had overstepped its legal authority by seeking to broadly compel this shift away from coal, a move the EPA calls the Best System of Emission Reduction, or BSER. The states and companies suing the EPA argue the agency doesn’t have the authority to regulate anything outside of a power plant itself."

Source:
$28 MILLION THIS WEEK
Here Come the Ad Buys
8 hours ago
THE LATEST

"Spending by super PACs tied to Donald Trump friends such as Ben Carson and banker Andy Beal will help make this week the general election's most expensive yet. Republicans and Democrats will spend almost $28 million on radio and television this week, according to advertising records, as Trump substantially increases his advertising buy for the final stretch. He's spending $6.4 million in nine states, part of what aides have said will be a $100 million television campaign through Election Day."

Source:
GOP REFUSED VOTE ON FCC COMMISIONER
Reid Blocks Tech Bill Over “Broken Promise”
13 hours ago
THE DETAILS

Monday night's debate may have inspired some in Congress, as Senate Minority Leader has decided to take a stand of his own. Reid is declining to allow a vote on a "bipartisan bill that would bolster U.S. spectrum availability and the deployment of wireless broadband." Why? Because of a "broken promise" made a year ago by Republicans, who have refused to vote on confirmation for a Democratic commissioner on the Federal Communications Commission to a second term. Harry Reid then took it a step further, invoking another confirmation vote still outstanding, that of Supreme Court nominee Merrick Garland.

Source:
FLINT FUNDING STILL AT ISSUE
Spending Bill Fails to Clear 60-Vote Hurdle
15 hours ago
THE LATEST
×